Claritas Pharmaceuticals Inc
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Claritas Pharmaceuticals Inc (CLAZF) - Net Assets
Latest net assets as of September 2021: $3.28 Million USD
Based on the latest financial reports, Claritas Pharmaceuticals Inc (CLAZF) has net assets worth $3.28 Million USD as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.02 Million) and total liabilities ($7.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.28 Million |
| % of Total Assets | 29.76% |
| Annual Growth Rate | 2.84% |
| 5-Year Change | -48.34% |
| 10-Year Change | -96.68% |
| Growth Volatility | 1186.11 |
Claritas Pharmaceuticals Inc - Net Assets Trend (2005–2020)
This chart illustrates how Claritas Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Claritas Pharmaceuticals Inc (2005–2020)
The table below shows the annual net assets of Claritas Pharmaceuticals Inc from 2005 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $1.51 Million | +143.85% |
| 2019-12-31 | $-3.44 Million | -135.20% |
| 2018-12-31 | $9.76 Million | +183.93% |
| 2017-12-31 | $-11.63 Million | -498.80% |
| 2016-12-31 | $2.92 Million | +561.45% |
| 2015-12-31 | $441.00K | +135.59% |
| 2014-12-31 | $-1.24 Million | -1.85% |
| 2013-12-31 | $-1.22 Million | -105.74% |
| 2012-12-31 | $21.18 Million | -53.28% |
| 2011-12-31 | $45.34 Million | +31.09% |
| 2010-12-31 | $34.59 Million | +40.53% |
| 2009-12-31 | $24.61 Million | +162.66% |
| 2008-12-31 | $9.37 Million | -67.85% |
| 2007-12-31 | $29.15 Million | +4031.65% |
| 2006-12-31 | $705.46K | -28.72% |
| 2005-12-31 | $989.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Claritas Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5485507560.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.51 Million | 3750.10% |
| Other Comprehensive Income | $56.51 Million | 3750.10% |
| Total Equity | $1.51 Million | 100.00% |
Claritas Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Claritas Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Synergy Grid and Development Phils Inc
PSE:SGP
|
$3.04K |
|
Everyman Media Group plc
LSE:EMAN
|
$3.05K |
|
Wolf Energy Services Inc.
PINK:WOEN
|
$3.05K |
|
SMT
VN:SMT
|
$3.06K |
|
DATANG INTL POW -H-
MU:BJI
|
$3.04K |
|
Ingdan Inc
STU:7C3
|
$3.04K |
|
PACIFIC CENTURY (PFQ.SG)
STU:PFQ
|
$3.04K |
|
Well Chip Group Berhad
KLSE:5325
|
$3.03K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Claritas Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -3,437,000 to 1,507,000, a change of 4,944,000.
- Net income of 4,210,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 734,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.21 Million | +279.36% |
| Other Comprehensive Income | $734.00K | +48.71% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Claritas Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $840.92 | $0.00 | x |
| 2006-12-31 | $599.37 | $0.00 | x |
| 2007-12-31 | $10965.84 | $0.00 | x |
| 2008-12-31 | $2732.71 | $0.00 | x |
| 2009-12-31 | $1605.95 | $0.00 | x |
| 2010-12-31 | $743.14 | $0.00 | x |
| 2011-12-31 | $431.27 | $0.00 | x |
| 2012-12-31 | $194.62 | $0.00 | x |
| 2013-12-31 | $-11.18 | $0.00 | x |
| 2014-12-31 | $-11.38 | $0.00 | x |
| 2015-12-31 | $0.60 | $0.00 | x |
| 2016-12-31 | $1.98 | $0.00 | x |
| 2017-12-31 | $-1.87 | $0.00 | x |
| 2018-12-31 | $0.89 | $0.00 | x |
| 2019-12-31 | $-0.15 | $0.00 | x |
| 2020-12-31 | $0.06 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Claritas Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 279.36%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.93x
- Recent ROE (279.36%) is above the historical average (-42.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -14.95% | 0.00% | 0.00x | 1.03x | $-246.98K |
| 2006 | -55.14% | 0.00% | 0.00x | 1.02x | $-459.55K |
| 2007 | -3.39% | 0.00% | 0.00x | 1.14x | $-3.90 Million |
| 2008 | -40.66% | -5768.18% | 0.00x | 1.51x | $-4.75 Million |
| 2009 | -15.32% | -229180.91% | 0.00x | 1.21x | $-6.23 Million |
| 2010 | -23.67% | -2028.11% | 0.01x | 1.28x | $-11.64 Million |
| 2011 | -48.56% | -1417.71% | 0.03x | 1.16x | $-26.55 Million |
| 2012 | -116.66% | -2616.47% | 0.03x | 1.41x | $-26.83 Million |
| 2013 | 0.00% | -4211.64% | 0.14x | 0.00x | $-19.89 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $72.65K |
| 2015 | -318.37% | 0.00% | 0.00x | 1.45x | $-1.45 Million |
| 2016 | -396.09% | 0.00% | 0.00x | 1.65x | $-11.85 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.70 Million |
| 2018 | 71.03% | 0.00% | 0.00x | 6.11x | $5.96 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.87 Million |
| 2020 | 279.36% | 0.00% | 0.00x | 6.93x | $4.06 Million |
Industry Comparison
This section compares Claritas Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Claritas Pharmaceuticals Inc (CLAZF) | $3.28 Million | -14.95% | 2.36x | $3.04K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |